Skip to main content
. Author manuscript; available in PMC: 2022 Jan 6.
Published in final edited form as: Annu Rev Pharmacol Toxicol. 2020 Aug 28;61:135–157. doi: 10.1146/annurev-pharmtox-031320-111453

Table 3.

Autoantibodies in Xenobiotic-Induced Autoimmunity and Autoimmune Disease.

Xenobiotic Autoimmune Diseases or Autoimmunitya Idiopathicb Xenobiotic Humanc Xenobiotic Experimentalc Selected References
Confident
Silica SLE,
SSc,
RA
ANA
DNA, Sm, RNP, SS-A/Ro, SS-B/La
Centromere,
DNA topoisomerase 1
RF
ACPAd
ANA
DNA
SS-A/Ro
SS-B/La
Centromere,
DNA topoisomerase 1
ACPA
ANA
Sm
RNP
dsDNA
RF
(21, 25, 30, 111,112,113)
(25, 29)
(123)
Smoking Seropositive RA RF
ACPA
ACPA (19)
Solvents SSc Scl-70 Scl-70 MDA
HNE
ssDNA
dsDNA
(126)
(95)
Insufficient evidence
Mercury autoantibodies, cytokines, nephrotic syndrome NA ANA ANA
Fibrillarin
Chromatin
(3)
Asbestos autoantibodies, atypical rheumatological symptoms NA ANA
dsDNA
RNP
SS-A/Ro52
Scl-70
Mesothelial cell
ANA
dsDNA
SS/A-Ro52
Mesothelial cell
(127)

Note: This table is not a comprehensive listing of all autoantibodies found in a particular idiopathic autoimmune disease. Rather it is a comparison of autoantibody responses found with a specific xenobiotic exposure and whether the same response has been identified in idiopathic disease.

a

Exposures leading to autoimmunity without clinical disease are mercury and asbestos.

b

Idiopathic disease means no known association with an environmental exposure.

c

Antibodies in humans or experimental animal models following exposure.

d

In italics, antibodies against post-translational protein modification.

e

Abbreviations: NA, not applicable.

HHS Vulnerability Disclosure